A5007034768- Lysosomal Storage Disorders Research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Psychosocial Factors Impacting Youth
- Biochemical and Molecular Research
- Chronic Myeloid Leukemia Treatments
- Virus-based gene therapy research
- Glycogen Storage Diseases and Myoclonus
- Child and Animal Learning Development
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Trypanosoma species research and implications
- Medical Imaging Techniques and Applications
- Educational Systems and Policies
- Statistical Methods and Bayesian Inference
- Myasthenia Gravis and Thymoma
- Prion Diseases and Protein Misfolding
- Photosynthetic Processes and Mechanisms
- Energy and Environmental Systems
- Gastroesophageal reflux and treatments
- Infant Health and Development
- Cultural Differences and Values
- Immunodeficiency and Autoimmune Disorders
- Healthcare Education and Workforce Issues
- Head and Neck Anomalies
- Nutrition, Health and Food Behavior
Yonsei University
2024
University of Michigan
2024
Ewha Womans University
2020
Gilead Sciences (United States)
2013-2015
7023 Background: IDELA (Zydelig) is a selective oral PI3Kδ inhibitor approved in combination with rituximab for previously treated pts CLL. This open-label study (NCT01659021) compared + OFA v relapsed Methods: Pts CLL progressing ≤ 24 mo from last therapy, who had received ≥ 2 cycles of purine analogue or bendamustine, were randomized 2:1 to either Arm A (IDELA 150 mg BID continuously plus OFA, 300 IV wk 1, then 1 gm wkly x 7 and q 4 4) B (OFA, same as except was substituted dosing)....
DNA is organized into chromatin-like structures that support the maintenance and regulation of genomes. A unique poorly understood form organization exists in chloroplasts, which are organelles endosymbiotic origin responsible for photosynthesis. Chloroplast genomes, together with associated proteins, membrane-less known as nucleoids. The internal arrangement nucleoid, molecular mechanisms organization, connections between nucleoid structure gene expression remain mostly unknown. We show
e18030 Background: Idelalisib (Zydelig), a first-in-class, selective, oral inhibitor of PI3Kδ, is approved in the US and EU for treatment chronic lymphocytic leukemia (CLL) combination with rituximab as monotherapy patients follicular lymphoma who have received at least two prior systemic therapies. Methods: An integrated analysis safety was conducted 760 subjects CLL, indolent non-Hodgkin lymphoma, or other B-cell malignancy IDELA alone (doses = 50 mg BID to 350 BID) part regimen (IDELA...
8526 Background: PI3K-delta signaling is critical for activation, proliferation and survival of B cells, plays a role in homing retention lymphoid tissues, hyperactive many B-cell malignancies. Idelalisib (GS-1101) first-in-class, selective, oral inhibitor PI3Kδ. Initial response rate 38% was reported previously iNHL (Kahl, ICML 2011). Long-term follow-up now presented. Methods: This phase 1 study evaluated the activity continuous idelalisib monotherapy pts with relapsed hematologic Doses...
Our purpose in this research was to develop a measure that reflected cross-cultural and cultural-specific expectations of “good mothering.” We based our on samples South Korean mothers ( n = 626) White the United States 612). developed an initial pool 74 items described good mothering both cultures. conducted exploratory confirmatory factor analyses separately for each group. found different structures: sample had three factors, States’ yielded four factors. Two these factors were similar...
8532 Background: Idelalisib (Zydelig), a selective oral inhibitor of PI3Kδ, demonstrated considerable anti-tumor activity in patients with relapsed/refractory iNHL phase 1 (p1; Flinn, 2014), and refractory 2 trials (p2; Gopal, 2014). This analysis evaluates the outcomes subset WM. Methods: Eligible WM (pts) included those disease (p1), or to both rituximab an alkylating agent (p2). dosages were 150 mg QD, 50 mg-200 BID PO (p2) administered continuously until progression. response was...
Mucopolysaccharidosis Type II (MPS II) is a X-linked lysosomal storage disease caused by deficiency of iduronate-2-sulfatase (I2S) leading to accumulation glycosaminoglycans and in the neuronopathic form, results irreversible neurocognitive decline. The objectives this study were better understand developmental trajectories patients with MPS across multiple domains identify timepoints where deviate outside typical development skill acquisition plateaus. This presents retrospective...